Cost of illness of breast cancer in low- and middle-income countries: a systematic review.
Health Econ Rev
; 14(1): 56, 2024 Jul 22.
Article
in En
| MEDLINE
| ID: mdl-39034345
ABSTRACT
This systematic review explores the cost of illness (COI) studies on breast cancer in low- to middle-income countries (LMICs). Studies in Cochrane, Proquest Thesis, PubMed and Scopus were considered. The reporting criteria were evaluated using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 statement. Studies must (1) be peer-reviewed, (2) report cost data, and (3) be full-text articles. Non-English articles were excluded. Twelve studies were included. The identified costs were made constant to 2022 USD values for reporting and comparison across studies. Annual costs per patient varied from $195 to $11,866 direct medical costs, $201 to $2233 direct non-medical costs and $332 to $26,390 productivity losses were reported. Cost differences were due to the cost types and components in each study. Only three COI studies reported sensitivity analysis and discount rates. Hence, it is recommended that future COI studies include an analysis of correlation between cost components and other variables.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Health Econ Rev
Year:
2024
Document type:
Article